Corbus Pharmaceuticals Holdings, Inc.

Equities

CRBP

US21833P3010

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
37.04 ^USD	+3.93%		-1.85%	+513.25%

Apr. 02	Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC	CI
Mar. 13	Corbus Pharmaceuticals Files Mixed Shelf	MT

Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 12, 2024 at 08:00 am EDT

Corbus Pharmaceuticals Holdings, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 44.6 million compared to USD 42.35 million a year ago. Basic loss per share from continuing operations was USD 10.31 compared to USD 10.15 a year ago.

Diluted loss per share from continuing operations was USD 10.31 compared to USD 10.15 a year ago.

Latest news about Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC	Apr. 02	CI
Corbus Pharmaceuticals Files Mixed Shelf	Mar. 13	MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $58 From $51, Maintains Outperform Rating	Mar. 13	MT
Health Care Climbs on Risk Appetite -- Health Care Roundup	Mar. 12	DJ
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
North American Morning Briefing : Powell Still in -2-	Mar. 07	DJ
Jefferies Upgrades Corbus Pharmaceuticals Holdings to Buy From Hold	Mar. 06	MT
Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer	Feb. 28	CI
Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024	Feb. 06	CI
Corbus Pharmaceuticals Closes $94.5 Million Public Offering	Feb. 02	MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $51 From $20, Maintains Outperform Rating	Jan. 29	MT
Top Premarket Decliners	Jan. 29	MT
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 26	MT
Sector Update: Health Care	Jan. 26	MT
Top Midday Gainers	Jan. 26	MT
Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701	Jan. 26	CI
Corbus Pharmaceuticals Holdings, Inc. Announces FDA Clearance of IND Application for its Anti-avb8 Monoclonal Antibody (CRB-601)	Jan. 09	CI
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $20 From $22, Maintains Outperform Rating	Nov. 08	MT
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Corbus Pharmaceuticals Holdings, Inc. Presents Results of Two Pre-Clinical Studies on its Anti-VETA>8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting	Nov. 02	CI
Transcript : Corbus Pharmaceuticals Holdings, Inc. - Special Call	23-10-10
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
North American Morning Briefing : Stock Futures -3-	23-05-11	DJ

Chart Corbus Pharmaceuticals Holdings, Inc.

Duration

Period

Chart Corbus Pharmaceuticals Holdings, Inc.

More charts

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFÎ² expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

35.64 USD

Average target price

55 USD

Spread / Average Target

+54.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CORBUS PHARMACEUTICALS HOLDINGS, INC.	+513.25%	374M
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.29B
ARGENX SE	+2.13%	22.18B
BIONTECH SE	-15.84%	21.2B
GENMAB A/S	-9.21%	18.31B
WUXI APPTEC CO., LTD.	-39.98%	17.38B
BEIGENE, LTD.	-14.65%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.97B
SAREPTA THERAPEUTICS, INC.	+31.35%	12.17B

Bio Therapeutic Drugs